With the S&P/ASX 200 closing lower at 5671 and all ordinaries at 5749.60, as energy and minerals stock are getting affected by the declining prices of oil, while the tech stocks have already taken a hit because of the sell off. Three stocks under such circumstances gaining attention are:
AUSTRALIAN VANADIUM LIMITED (ASX: AVL) â To offer in-kind services to the Future Batteries Industry Cooperative Research Centre the company has signed an agreement. AVL presently hold 7.5 million shares and 1.25 million listed options in Bryah which represents a 13.31% holding in that company. As at 30 June 2018 the group had cash reserves worth of $5,152,782 compared to the reserves in 2017 of $1,524,171. The net assets of the Group have increased by $5,121,171 mainly due to advancement of the vanadium in energy storage strategy, ongoing exploration and evaluation of the Gabanintha Vanadium and Blesberg Projects and capital raising. The stock traded at a market price of $0.029 with a daily percentage change of positive 7.407% as at November 26, 2018. It has undergone a performance change of an attractive 50.00% over the past 12 months.
ZYBER HOLDINGS LTD (ASX: ZYB) â The consolidated statement of comprehensive income shows a net loss attributable to members of $934,699 as compared to 2017 loss of $2,067,229. As a free beta product, the Zyber development team completed the launch of the Zyber Enterprise application during the first quarter. The current assets are of $1,050,303 and current liabilities are of $61,744 which represents the companyâs ability to pay short term obligations. The cash and cash equivalents at end of financial year was at $1,001,728 in June 30, 2018 and $1,745,049 in June 30, 2017 with no debt on the balance sheet which represents a healthy balance sheet. The stock traded at a market price of $0.014 with a daily percentage change of positive 40% as at November 26, 2018. It has undergone a performance change of 25.00% over the past six months.
BARD1 LIFE SCIENCES LIMITED (ASX: BD1) â To deliver value to shareholders the company is exploring multiple partnering and corporate opportunities. The company is focussing on fulfilling unmet needs in global cancer diagnostics market of US $101 billion. Lately, company has made substantial achievements with NEW BC-001 results showing high accuracy of BARD1-Breast for detection of breast cancer with 88% specificity and 70% sensitivity and Chinese Divisional Patent granted covering BARD1-Lung. Over the next 6 - 12 months multiple value-adding milestones are expected by the company. BD1 has growth potential when compared to the peer group with A$19.06m at development-stage blood tests for early detection of breast, ovarian and lung cancers. The stock traded at a market price of $0.025 with a daily percentage change of positive 8.696% as at November 26, 2018. It has undergone a performance change of an attractive 193.88% over the past 12 months.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.